G. Steven Burrill

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer， Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as a member of the Boards of Directors of Catalyst Biosciences， Depomed （NASDAQ: DEPO）， NewBridge Pharmaceuticals， Proventys， Targacept （NASDAQ: TRGT）， and Expression Diagnostics （XDx）. He previously served as Chairman of the Boards of Abunda Nutrition， BioImagene and Pharmasset. Prior to founding Burrill & Company in 1994， he spent 28 years with Ernst & Young， directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/ manufacturing industries worldwide. In 2002， Mr. Burrill was recognized as a biotech investment visionary by the prestigious Scientific American magazine （The Scientific American 50）， as well as being honored at the American Liver Foundation’s Annual “Salute to Excellence” Gala， which honors the best and the brightest from the Bay Area’s medical， biotech and bio-pharmaceutical industries. In 2008 he received the BayBio Pantheon 2008 DiNA lifetime achievement award for his worldwide biotech leadership.